Checking immunotherapy and chemo before lung surgery for stage III cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests giving toripalimab plus another treatment (JS004) together with standard chemotherapy before lung surgery for stage IIIB–IIIC non-small cell lung cancer. It may help shrink the tumor and make surgery more effective, and it compares different treatment combinations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to join the study by signing an informed consent form
- You’re 18 years or older, and your lung cancer was confirmed by biopsy
- Your cancer is stage IIIB or IIIC, and scans show no spread to distant sites
- Your daily function is good (ECOG 0 or 1) and you can likely tolerate surgery
- You have at least one measurable tumor spot on scans
- You do not have conditions that would make treatment unsafe (for example: unstable heart/liver/kidney problems, active infections, or interstitial lung disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy given before surgery to remove stage III lung cancer. The goal is to shrink the tumor and improve survival chances by boosting your immune system to fight the cancer.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
Hear when a new Stage III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.